{"id":"dcp-001","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1928616","moleculeType":"Small molecule","molecularWeight":"650.72"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, DCP-001 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as empagliflozin and canagliflozin, which are used to treat type 2 diabetes.","oneSentence":"DCP-001 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:28.060Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04739527","phase":"PHASE1","title":"Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2021-06-10","conditions":"Ovarian Cancer","enrollment":17},{"nctId":"NCT03697707","phase":"PHASE2","title":"Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia","status":"UNKNOWN","sponsor":"Mendus","startDate":"2018-10-15","conditions":"Acute Myeloid Leukemia in Remission","enrollment":20},{"nctId":"NCT01373515","phase":"PHASE1, PHASE2","title":"Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Mendus","startDate":"2011-04","conditions":"Acute Myeloid Leukemia (AML), Leukemic Dendritic Cell Vaccination","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DCP-001","genericName":"DCP-001","companyName":"Mendus","companyId":"mendus","modality":"Biologic","firstApprovalDate":"","aiSummary":"DCP-001 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}